IR

• 31 Jul, 2023
  Spago Nanomedical interim report January-June 2023
• 31 Jul, 2023
  Spago Nanomedical delårsrapport januari-juni 2023
• 28 Jun, 2023
  Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02
• 28 Jun, 2023
  Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02
• 13 Jun, 2023
  Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd
• 13 Jun, 2023
  Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board
• 23 May, 2023
  Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study
• 23 May, 2023
  Spago Nanomedical har lämnat in ansökan om att starta klinisk fas I/IIa-studie med Tumorad®
• 10 May, 2023
  Kommuniké från årsstämma 2023 i Spago Nanomedical AB
• 10 May, 2023
  Bulletin from the 2023 Annual General Meeting of Spago Nanomedical AB